A USA registry of gastrointestinal stromal tumor patients: Changes in practice over time and differences between community and academic practices

Annals of Oncology

Volumn 22, Issue 11, 2011, Pages 2523-2529

  Pisters, P W T ^a   Blanke, C D ^b   von Mehren, M ^c   Picus, J ^d   Sirulnik, A ^e   Stealey, E ^e   Trent, J C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c FOX CHASE CANCER CENTER   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Gastrointestinal stromal tumors; Registry; Survival; Tyrosine kinase inhibitor

Indexed keywords

CYTOTOXIC AGENT; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CLINICAL PRACTICE; COMMUNITY CARE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC KIT; DISEASE REGISTRY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG UTILIZATION; ECHOGRAPHY; ENDOSCOPY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MUTATIONAL ANALYSIS; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; SURVIVAL; TREATMENT DURATION; TREND STUDY; TUMOR LOCALIZATION; UNITED STATES; VISCERAL METASTASIS;

EID: 80355143677     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq773     Document Type: Article

References (15)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Soft Tissue Sarcoma Version 1.2010 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp 31 March 2010, date last accessed).
2. de Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol Oncol Res 2003; 9: 13-19.
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Soft Tissue Sarcoma Version 1. 2007. J Nat Comp Cancer Netw 2007; 5(4): 364.
5. Tryggvason G, Gíslason HG, Magnússon MK, Jó nasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a populationbased incidence and pathologic risk stratification study. Int J Cancer 2005; 117: 289-293.
6. Nilsson B, Bü mming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. A population-based study in western Sweden. Cancer 2005; 103: 821-829.
7. DeMatteo D, Owzar E, Maki R et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Proc Am Soc Clin Oncol 2008; 26 Abstr 10079.
8. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26(4): 620-625.
9. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet 2004; 364(9440): 1127-1134.
10. Verweij J, van Oosterom A, Blay JY et al. Imatinib mesylate (ST1-571 Glivec,Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39(14): 2006-2011.
11. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006; 368(9544): 1329-1338.
12. George S, Blay JY, Casali PG et al. Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in patients with advanced GIST [ASCO Annual Meeting Proceedings Part I]. J Clin Oncol 2007; 25 (18S) (Abstr 10015).
13. George S, Blay JY, Casali PG et al. Continuous daily dosing (CDD0 of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, PK and pharmacodynamic analysis. J Clin Oncol 2008; 26: Abstr 10554.
14. DeMatteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomized, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104.
15. Casali PG, Blay J- Y. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v98-v102.